^
Association details:
| Biomarker: | SEMA6D underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | epirubicin (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer
Published date:
12/09/2021
Excerpt:
Cells with reduced expression of SEMA6D were significantly more resistant to epirubicin both at the lower dose for the MTT assays (p < 0.05) and in the clonogenic survival assays (p < 0.01). We concluded that reduced SEMA6D expression caused relative epirubicin resistance, and therefore that miR-195 mediates chemoresponse, at least in part, through SEMA6D.
DOI:
10.3390/cancers13235979
